1. Ciprofibrate therapy in patients with hypertriglyceridemia and low high density lipoprotein (HDL)-cholesterol: greater reduction of non-HDL cholesterol in subjects with excess body weight (The CIPROAMLAT study)
- Author
-
Medel Octavio, Hernández Ismael, Salinas Saul, Vazquez Cuauhtémoc, Ramírez Erika, Jiménez Sergio, Hernández Ma, Florenzano Fernando, Saavedra Victor, Reyes Eliana, Machado Carlos, Oliveira José, Torres Kerginaldo, Rabelo Lísia, Neto Abrahão, Filho José, Rengifo Hector, Stockins Benjamín, Aguilar-Salinas Carlos A, Assis-Luores-Vale Andréia, Moreno Ricardo, Lugo Paula, Alvarado Ricardo, Mehta Roopa, Gutierrez Victor, and Gómez Pérez Francisco J
- Subjects
Ciprofibrate ,obesity ,HDL cholesterol ,triglycerides ,fibrates ,Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Abstract
Abstract Background Hypertriglyceridemia in combination with low HDL cholesterol levels is a risk factor for cardiovascular disease. Our objective was to evaluate the efficacy of ciprofibrate for the treatment of this form of dyslipidemia and to identify factors associated with better treatment response. Methods Multicenter, international, open-label study. Four hundred and thirty seven patients were included. The plasma lipid levels at inclusion were fasting triglyceride concentrations between 1.6–3.9 mM/l and HDL cholesterol ≤ 1.05 mM/l for women and ≤ 0.9 mM/l for men. The LDL cholesterol was below 4.2 mM/l. All patients received ciprofibrate 100 mg/d. Efficacy and safety parameters were assessed at baseline and at the end of the treatment. The primary efficacy parameter of the study was percentage change in triglycerides from baseline. Results After 4 months, plasma triglyceride concentrations were decreased by 44% (p < 0.001). HDL cholesterol concentrations were increased by 10% (p < 0.001). Non-HDL cholesterol was decreased by 19%. A greater HDL cholesterol response was observed in lean patients (body mass index < 25 kg/m2) compared to the rest of the population (8.2 vs 19.7%, p < 0.001). In contrast, cases with excess body weight had a larger decrease in non-HDL cholesterol levels (-20.8 vs -10.8%, p < 0.001). There were no significant complications resulting from treatment with ciprofibrate. Conclusions Ciprofibrate is efficacious for the correction of hypertriglyceridemia / low HDL cholesterol. A greater decrease in non-HDL cholesterol was found among cases with excess body weight. The mechanism of action of ciprofibrate may be influenced by the pathophysiology of the disorder being treated.
- Published
- 2004
- Full Text
- View/download PDF